Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs
Phase 3
- Conditions
- Acute ischemic stroke (excluding cardioembolic stroke)
- Registration Number
- JPRN-UMIN000000758
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 770
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients having a history of coronary, renal, hepatic or metabolic disease. Patients exhibiting dysemia (2) Other conditons at the discretion of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dichotomized mRS score
- Secondary Outcome Measures
Name Time Method Comparison between mRS groups, JSS-M scores